| Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin S Colombetti, V Basso, DL Mueller, A Mondino The Journal of Immunology 176 (5), 2730-2738, 2006 | 920 | 2006 |
| Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation R Palumbo, M Sampaolesi, F De Marchis, R Tonlorenzi, S Colombetti, ... The Journal of cell biology 164 (3), 441-449, 2004 | 619 | 2004 |
| A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ... Clinical Cancer Research 22 (13), 3286-3297, 2016 | 338 | 2016 |
| Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ... Science translational medicine 12 (534), eaav7431, 2020 | 289 | 2020 |
| Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy C Claus, C Ferrara, W Xu, J Sam, S Lang, F Uhlenbrock, R Albrecht, ... Science translational medicine 11 (496), eaav5989, 2019 | 209 | 2019 |
| CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies M Bacac, S Colombetti, S Herter, J Sam, M Perro, S Chen, R Bianchi, ... Clinical Cancer Research 24 (19), 4785-4797, 2018 | 178 | 2018 |
| PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells L Codarri Deak, V Nicolini, M Hashimoto, M Karagianni, PC Schwalie, ... Nature 610 (7930), 161-172, 2022 | 100 | 2022 |
| IL-7 adjuvant treatment enhances long-term tumor antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector S Colombetti, F Lévy, L Chapatte Blood, The Journal of the American Society of Hematology 113 (26), 6629-6637, 2009 | 84 | 2009 |
| Clonal anergy is maintained independently of T cell proliferation S Colombetti, F Benigni, V Basso, A Mondino The Journal of Immunology 169 (11), 6178-6186, 2002 | 73 | 2002 |
| In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell … S Lehmann, R Perera, HP Grimm, J Sam, S Colombetti, T Fauti, L Fahrni, ... Clinical Cancer Research 22 (17), 4417-4427, 2016 | 67 | 2016 |
| Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy I Waldhauer, V Gonzalez-Nicolini, A Freimoser-Grundschober, TK Nayak, ... MAbs 13 (1), 1913791, 2021 | 61 | 2021 |
| Xotx5b, a new member of the Otx gene family, may be involved in anterior and eye development in Xenopus laevis R Vignali, S Colombetti, G Lupo, W Zhang, S Stachel, RM Harland, ... Mechanisms of development 96 (1), 3-13, 2000 | 58 | 2000 |
| Efficient Induction of Tumor Antigen–Specific CD8+ Memory T Cells by Recombinant Lentivectors L Chapatte, S Colombetti, JC Cerottini, F Lévy Cancer research 66 (2), 1155-1160, 2006 | 55 | 2006 |
| Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity J Sam, S Colombetti, T Fauti, A Roller, M Biehl, L Fahrni, V Nicolini, ... Frontiers in Oncology 10, 575737, 2020 | 39 | 2020 |
| Application of a MABEL approach for a T-cell-bispecific monoclonal antibody: CEA TCB S Dudal, H Hinton, AM Giusti, M Bacac, M Muller, T Fauti, S Colombetti, ... Journal of Immunotherapy 39 (7), 279-289, 2016 | 32 | 2016 |
| Lentivector immunization induces tumor antigen‐specific B and T cell responses in vivo J Garcia Casado, J Janda, J Wei, L Chapatte, S Colombetti, P Alves, ... European journal of immunology 38 (7), 1867-1876, 2008 | 28 | 2008 |
| Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model F Cremasco, E Menietti, D Speziale, J Sam, S Sammicheli, M Richard, ... PLoS One 16 (1), e0241091, 2021 | 27 | 2021 |
| CD20 Tcb (RG6026), a novel" 2: 1" T cell bispecific antibody for the treatment of B cell malignancies M Bacac, P Umaña, S Herter, S Colombetti, J Sam, M Le Clech, ... Blood 128 (22), 1836, 2016 | 27 | 2016 |
| Rapamycin‐sensitive signals control TCR/CD28‐driven Ifng, Il4 and Foxp3 transcription and promoter region methylation R Tomasoni, V Basso, K Pilipow, G Sitia, S Saccani, A Agresti, F Mietton, ... European journal of immunology 41 (7), 2086-2096, 2011 | 27 | 2011 |
| Breast cancer suppressor candidate‐1 (BCSC‐1) is a melanoma tumor suppressor that down regulates MITF SI Anghel, R Correa‐Rochal, E Budinska, KF Boliganl, S Abraham, ... Pigment cell & melanoma research 25 (4), 482-487, 2012 | 24 | 2012 |
